Answers are grounded in this paper and cite their sources.
Observational findings suggest tenofovir alafenamide lowers HCC risk in chronic hepatitis B patients, indicating potential benefits for treatment choices.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Kang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: